A new generation of weight loss and blood sugar lowering drugs Mazdutide is a glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist jointly developed by Innovent Biologics and Eli Lilly and Company , As an oxyntomodulin (OXM) analog, Mastolide can not only promote insulin secretion, lower blood sugar and reduce weight by stimulating GLP-1R, but also increase energy consumption and enhance weight loss efficacy by stimulating GCGR, while improving liver fat metabolism . Mazdutide has demonstrated excellent weight loss and blood sugar lowering efficacy in many clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes and liver fat content, and improving insulin sensitivity, bringing multiple metabolic benefits. On June 27, 2025, the National Medical Products Administration approved the listing of Mastolide Injection (trade name: Xinermei), a Class 1 innovative drug applied by Innovent Biologics (Suzhou) Co., Ltd. This drug is suitable for long-term weight control of adult patients based on diet control and increased physical activity. The initial body mass index (BMI) is: BMI ≥ 28 kg/m2 (obesity); or BMI ≥ 24 kg/m2 (overweight), accompanied by at least one weight-related comorbidity (such as hyperglycemia, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome, etc.).

On September 19, 2025, the second indication of Mashidu peptide injection was approved by the National Medical Products Administration for blood sugar control in adult patients with type 2 diabetes. [28] The launch of this drug provides patients with a new treatment option